免疫检查点抑制剂临床联合治疗研究进展

发布时间：2018-05-09 03:23

  本文选题：肿瘤免疫治疗 + 免疫检查点抑制剂　； 参考：《中国新药杂志》2017年23期

【摘要】：肿瘤细胞可表达一些免疫检查点分子,以逃避免疫系统的识别和攻击。最近几年,以程序性死亡因子(PD-1/PD-L1)和细胞毒T淋巴细胞抗原4(CTLA-4)为靶点的免疫检查点抑制剂陆续获FDA批准上市。虽然有些患者经以上药物治疗后出现完全缓解或生存期延长,但尚存在较大比例的患者并未从中获益,而联合用药成为克服这一局限的有效方式。派姆单抗与化疗联用后因其出色的表现,已成为非小细胞肺癌的一线治疗方式。伊匹单抗与纳武单抗在黑色素瘤中联用较纳武单抗单用的客观缓解率显著提高,成为黑色素瘤的一线治疗选择。除了以上获批的几种联用方案,大量免疫检查点抑制剂与化疗、靶向治疗、疫苗、放疗、免疫调节剂及其他治疗方式等联合用药的临床研究正在开展,以期为临床联合用药提供参考和依据。
[Abstract]:Tumor cells can express some immune checkpoint molecules to escape the recognition and attack of the immune system. In recent years, immunocheckpoint inhibitors targeting PD-1 / PD-L1 and cytotoxic T lymphocyte antigen 4CTLA-4) have been approved by FDA. Although some patients had complete remission or prolonged survival after the treatment of the above drugs, there was still a large proportion of patients who did not benefit from it, and combined use of drugs became an effective way to overcome this limitation. Pam monoclonal antibody combined with chemotherapy has become a first-line treatment for non-small cell lung cancer due to its excellent performance. The objective remission rate of combined use of ipiumab and navumab in melanoma was significantly higher than that of Navelumab and became the first line treatment option for melanoma. In addition to the several combination schemes approved above, a large number of clinical studies of immunocheckpoint inhibitors combined with chemotherapy, targeted therapy, vaccines, radiotherapy, immunomodulators and other treatment methods are under way. In order to provide reference and basis for clinical combined use of drugs.
【作者单位】： 首都医科大学附属北京朝阳医院药事部;
【基金】：国家自然科学基金资助项目(81703611) 北京市自然科学基金资助项目(7164262)
【分类号】：R730.5
，

本文编号：1864359